Lv3
380 积分 2023-06-14 加入
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort
6个月前
已完结
Provider/vendor marriage: winning through cooperation
7个月前
已关闭
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
9个月前
已完结
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
11个月前
已完结
New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer
11个月前
已关闭
A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor
11个月前
已完结
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
11个月前
已完结
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
11个月前
已完结
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
1年前
已完结
皖公网安备34019202002308
